Mereo BioPharma Group (NASDAQ:MREO) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Posted by Renee Jackson on Mar 28th, 2025

Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03), Zacks reports.

Mereo BioPharma Group Price Performance

Shares of Mereo BioPharma Group stock opened at $2.41 on Friday. Mereo BioPharma Group has a twelve month low of $2.22 and a twelve month high of $5.02. The company’s fifty day moving average is $2.73 and its 200 day moving average is $3.51.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. initiated coverage on shares of Mereo BioPharma Group in a research note on Thursday. They issued an “overweight” rating and a $7.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a report on Tuesday, March 18th. Lifesci Capital began coverage on shares of Mereo BioPharma Group in a research note on Tuesday, December 24th. They issued an “outperform” rating and a $10.00 price objective for the company. Finally, Jefferies Financial Group started coverage on shares of Mereo BioPharma Group in a research note on Friday, December 6th. They set a “buy” rating and a $7.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $7.71.

Check Out Our Latest Stock Analysis on MREO

About Mereo BioPharma Group

(Get Free Report)

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.